Study of radiation, chemo, and immunotherapy for advanced pancreatic cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of chemotherapy (GnP), an immunotherapy drug (serplulimab), and targeted radiation (SBRT) as a first treatment for locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this triple therapy can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with locally advanced pancreatic cancer that cannot be surgically removed.
- You have not received any previous cancer treatment for this disease, including chemotherapy, radiation, or surgery.
- You are between 18 and 75 years old.
- You are in reasonably good health (able to care for yourself, up and about more than half of waking hours).
- Your tumor is measurable on a CT scan (at least 1 cm across).
- Your blood counts, liver, kidney, and heart function are adequate based on lab tests.
- You do not have an active autoimmune disease or take strong immune-suppressing medicines.
- You have not had another cancer in the past 5 years (except for treated skin or cervical cancer).
- You are not pregnant and are willing to use contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, an immunotherapy drug (adebrelimab) and a chemotherapy regimen (NALIRIFOX) before any surgery, for people with locally advanced pancreatic cancer. The goal is to shrink the tumor enough to make surgery possible, potentially improving outcomes.
This trial tests a new combination of treatments for pancreatic cancer that has spread. It adds a type of immunotherapy (called serplulimab) and targeted radiation (SBRT) to the usual chemotherapy, to see if it works better than chemotherapy alone in shrinking the cancer and helping you live longer.
This trial tests a new combination of drugs and radiation for people with pancreatic cancer that has spread. It aims to shrink tumors and improve quality of life by using an immunotherapy drug, two chemotherapies, and precisely targeted radiation.
This trial tests a new combination of drugs with radiation therapy for people with locally advanced pancreatic cancer that cannot be removed with surgery. The treatment aims to shrink the tumor and improve outcomes.
This trial tests a new approach that combines a special type of radiation therapy (called PRaG) with an immunotherapy drug to treat advanced pancreatic cancer that hasn't spread. The goal is to see if this combination can shrink or control the tumor and help you live longer.
This trial compares two different chemotherapy combinations, each paired with immunotherapy and radiation, as the first treatment for locally advanced pancreatic cancer. It aims to see which combination works better.
Hear when a new Locally Advanced Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.